Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study von Robert, Caroline, Prof, Ribas, Antoni, Prof, Schachter, Jacob, Prof, Arance, Ana, MD, Grob, Jean-Jacques, Prof, Mortier, Laurent, Prof, Daud, Adil, Prof, Carlino, Matteo S, MB, McNeil, Catriona M, MD, Lotem, Michal, Prof, Larkin, James M G, Prof, Lorigan, Paul, Prof, Neyns, Bart, Prof, Blank, Christian U, Prof, Petrella, Teresa M, MD, Hamid, Omid, MD, Su, Shu-Chih, PhD, Krepler, Clemens, MD, Ibrahim, Nageatte, MD, Long, Georgina V, Prof

Volltext

The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival von Valpione, Sara, Mundra, Piyushkumar A., Galvani, Elena, Campana, Luca G., Lorigan, Paul, De Rosa, Francesco, Gupta, Avinash, Weightman, John, Mills, Sarah, Dhomen, Nathalie, Marais, Richard

Volltext

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer von Reck, Martin, Luft, Alexander, Szczesna, Aleksandra, Havel, Libor, Kim, Sang-We, Akerley, Wallace, Pietanza, Maria Catherine, Wu, Yi-Long, Zielinski, Christoph, Thomas, Michael, Felip, Enriqueta, Gold, Kathryn, Horn, Leora, Aerts, Joachim, Nakagawa, Kazuhiko, Lorigan, Paul, Pieters, Anne, Kong Sanchez, Teresa, Fairchild, Justin, Spigel, David

Volltext

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022 von Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Basset-Seguin, Nicole, Bastholt, Lars, Bataille, Veronique, del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria C., Forsea, Ana-Maria, Grob, Jean-Jacques, Hoeller, Christoph, Kaufmann, Roland, Kelleners-Smeets, Nicole, Lallas, Aimilios, Lebbé, Celeste, Lytvynenko, Bodhan, Malvehy, Josep, Moreno-Ramirez, David, Nathan, Paul, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J., Van Akkooi, Alexander C.J., Vieira, Ricardo, Zalaudek, Iris, Lorigan, Paul

Volltext

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial von Eggermont, Alexander M M, Blank, Christian U, Mandala, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline

Volltext

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial von Faivre-Finn, Corinne, Prof, Snee, Michael, DM, Ashcroft, Linda, MSc, Appel, Wiebke, MD, Barlesi, Fabrice, Prof, Bhatnagar, Adityanarayan, MD, Bezjak, Andrea, MD, Cardenal, Felipe, PhD, Fournel, Pierre, Prof, Harden, Susan, DM [Oxon], Le Pechoux, Cecile, MD, McMenemin, Rhona, MSc, Mohammed, Nazia, FRCR, O'Brien, Mary, MD, Pantarotto, Jason, MD, Surmont, Veerle, Prof, Van Meerbeeck, Jan P, Prof, Woll, Penella J, Prof, Lorigan, Paul, Prof, Blackhall, Fiona, Prof

Volltext

Neoadjuvant immunotherapy for melanoma is now ready for clinical practice von Garbe, Claus, Dummer, Reinhard, Amaral, Teresa, Amaria, Rodabe N., Ascierto, Paolo A., Burton, Elizabeth M., Dreno, Brigitte, Eggermont, Alexander M. M., Hauschild, Axel, Hoeller, Christoph, Kaufmann, Roland, Lebbe, Celeste, Mandala, Mario, Menzies, Alexander M., Moreno, David, Michielin, Olivier, Nathan, Paul, Patel, Sapna P., Robert, Caroline, Schadendorf, Dirk, Lorigan, Paul C., Scolyer, Richard A., Tawbi, Hussein A., van de Wiel, Bart A., Blank, Christian, Long, Georgina V.

Volltext

Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis von Ogungbenro, Kayode, Patel, Alkesh, Duncombe, Robert, Nuttall, Richard, Clark, James, Lorigan, Paul

Volltext

Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy von Valpione, Sara, Galvani, Elena, Tweedy, Joshua, Mundra, Piyushkumar A, Banyard, Antonia, Middlehurst, Philippa, Barry, Jeff, Mills, Sarah, Salih, Zena, Weightman, John, Gupta, Avinash, Gremel, Gabriela, Baenke, Franziska, Dhomen, Nathalie, Lorigan, Paul C, Marais, Richard

Volltext

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma von RIBAS, Antoni, KEFFORD, Richard, LORIGAN, Paul, KENDRA, Kari L, MAIO, Michele, TREFZER, Uwe, SMYLIE, Michael, MCARTHUR, Grant A, DRENO, Brigitte, NATHAN, Paul D, MACKIEWICZ, Jacek, KIRKWOOD, John M, MARSHALL, Margaret A, GOMEZ-NAVARRO, Jesus, BO HUANG, PAVLOV, Dmitri, HAUSCHILD, Axel, PUNT, Cornelis J. A, HAANEN, John B, MARMOL, Maribel, GARBE, Claus, GOGAS, Helen, SCHACHTER, Jacob, LINETTE, Gerald

Volltext

PD-L1 expression as a potential predictive biomarker von Fusi, Alberto, Festino, Lucia, Botti, Gerado, Masucci, Giuseppe, Melero, Ignacio, Lorigan, Paul, Ascierto, Paolo A

Volltext

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant... von Garbe, Claus, Keim, Ulrike, Amaral, Teresa, Berking, Carola, Eigentler, Thomas K, Flatz, Lukas, Gesierich, Anja, Leiter, Ulrike, Stadler, Rudolf, Sunderkötter, Cord, Tüting, Thomas, Utikal, Jochen, Wollina, Uwe, Zimmer, Lisa, Zouboulis, Christos C, Ascierto, Paolo A, Eggermont, Alexander M M, Grob, Jean-Jacques, Hauschild, Axel, Sekulovic, Lidija Kandolf, Long, Georgina V, Luke, Jason J, Michielin, Olivier, Peris, Ketty, Schadendorf, Dirk, Kirkwood, John M, Lorigan, Paul C

Volltext

Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors von Switzer, Benjamin, Haanen, John, Lorigan, Paul C, Puzanov, Igor, Turajlic, Samra

Volltext

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma von Girotti, Maria Romina, Gremel, Gabriela, Lee, Rebecca, Galvani, Elena, Rothwell, Dominic, Viros, Amaya, Mandal, Amit Kumar, Lim, Kok Haw Jonathan, Saturno, Grazia, Furney, Simon J, Baenke, Franziska, Pedersen, Malin, Rogan, Jane, Swan, Jacqueline, Smith, Matthew, Fusi, Alberto, Oudit, Deemesh, Dhomen, Nathalie, Brady, Ged, Lorigan, Paul, Dive, Caroline, Marais, Richard

Volltext

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma von Khoja, Leila, Lorigan, Paul, Zhou, Cong, Lancashire, Matthew, Booth, Jessica, Cummings, Jeff, Califano, Raffaele, Clack, Glen, Hughes, Andrew, Dive, Caroline

Volltext

Checkpoint inhibitor‐associated bullous cutaneous immune‐related adverse events: a multicentre observational study von Kawsar, Anusuya, Edwards, Charlotte, Patel, Pooja, Heywood, Richard M., Gupta, Aakriti, Mann, Jasmine, Harland, Christopher, Heelan, Kara, Larkin, James, Lorigan, Paul, Harwood, Catherine A., Matin, Rubeta N., Fearfield, Louise

Volltext

Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients von IVES, Natalie J, STOWE, Rebecca L, LORIGAN, Paul, WHEATLEY, Keith

Volltext

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma von Girotti, Maria R, Pedersen, Malin, Sanchez-Laorden, Berta, Viros, Amaya, Turajlic, Samra, Niculescu-Duvaz, Dan, Zambon, Alfonso, Sinclair, John, Hayes, Andrew, Gore, Martin, Lorigan, Paul, Springer, Caroline, Larkin, James, Jorgensen, Claus, Marais, Richard

Volltext

T cell immune awakening in response to immunotherapy is age-dependent von Salih, Zena, Banyard, Antonia, Tweedy, Joshua, Galvani, Elena, Middlehurst, Philippa, Mills, Sarah, Weightman, John, Gupta, Avinash, Lorigan, Paul C., Zhou, Cong, Dhomen, Nathalie, Valpione, Sara, Marais, Richard

Volltext

Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma von Kreft, Sophia, Gesierich, Anja, Eigentler, Thomas, Franklin, Cindy, Valpione, Sara, Ugurel, Selma, Utikal, Jochen, Haferkamp, Sebastian, Blank, Christian, Larkin, James, Garbe, Claus, Schadendorf, Dirk, Lorigan, Paul, Schilling, Bastian

Volltext